

Chlamydia Drug Development Pipeline Study, H2 2018

<https://marketpublishers.com/r/C6E46C5DB20EN.html>

Date: August 2018

Pages: 60

Price: US\$ 1,200.00 (Single User License)

ID: C6E46C5DB20EN

Abstracts

Chlamydia Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Chlamydia pipeline products.

DISEASE OVERVIEW

Chlamydia infections are caused by Chlamydia trachomatis bacteria. Worldwide, the annual prevalence of the sexually transmitted infection (STD) is estimated to be over 100 million. As limited or no symptoms are presented in initial period, the Chlamydia patients go for treatment in late stages. Amidst lack of vaccines available for prevention of the Chlamydia infection, 10 companies are actively developing the Chlamydia Infection pipeline drugs. Both genders are equally infected by the disease. In women, reproductive system can be infected, resulting in permanent damages and premature deliveries. Antibiotics are mainly given to patients who are infected by the disease.

Abera Bioscience AB, BlueWillow Biologics, Evofem Biosciences Inc, Genetic Immunity Inc, Genocea Biosciences, Lead Discovery Center GmbH, Melinta Therapeutics, Prokarium Ltd, QureTech Bio AB, and Vault Pharma Inc are actively investing their R&D efforts in development of vaccines and treatment solutions for Chlamydia infections.

REPORT DESCRIPTION

The Chlamydia pipeline guide presents complete overview of drugs currently being developed for Chlamydia. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the

Chlamydia pipeline candidate.

Research and Development progress along with latest news related to each of the Chlamydia pipeline candidates is included.

Major companies participating in therapeutic development of Chlamydia are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Chlamydia from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Chlamydia clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Chlamydia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF CHLAMYDIA PIPELINE REPORT INCLUDES

Panorama of Chlamydia pipeline markets including statistics on therapeutic drugs and companies involved

Chlamydia Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered

Chlamydia pipeline candidates across various 'Mechanism of Actions' are also presented in the study

Overview of companies participating in Chlamydia pipeline with short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

Research and Development progress and trial details, results wherever

available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Chlamydia pipeline therapeutics

REASONS TO BUY

Get clear understanding of the entire Chlamydia pipeline, with details on active projects

Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global Chlamydia pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Chlamydia Pipeline include-
 - Number of Companies with Chlamydia projects in pre-clinical Development-
 - Number of Companies with Chlamydia projects in Clinical Development-
 - Chlamydia Pipeline Companies based in Americas
 - Chlamydia Pipeline Companies based in Europe
 - Chlamydia Pipeline Companies based in Asia Pacific
 - Chlamydia Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
 - Chlamydia Pipeline Agents in pre- clinical/Discovery stage of Development
 - Chlamydia Pipeline Agents in Clinical Development stage
 - Chlamydia Pipeline Therapeutic Compounds received special status
 - Mechanism of Action of most pipeline Drugs-
 - Small molecules among the Chlamydia Pipeline agents

II. INSIGHTS INTO CHLAMYDIA PIPELINE

1. Disease Overview
 - Introduction to Chlamydia
 - Symptoms and Causes of Chlamydia
 - Treatment or Prevention Options for Chlamydia
 - Other Details
2. Phase wise Pipeline Compounds
 - Chlamydia Pipeline- Pre- Clinical/Discovery stage Drugs
 - Chlamydia Pipeline- Phase 1 stage Drugs
 - Chlamydia Pipeline- Phase 2 stage Drugs
 - Chlamydia Pipeline- Phase 3 stage Drugs
 - Chlamydia Pipeline- Pre-Registration stage Drugs
3. Company wise Chlamydia Pipeline Compounds
4. Chlamydia Pipeline by Mechanism of Action

III. CHLAMYDIA PIPELINE COMPOUND DETAILS

Ab03
NE based chlamydia vaccine
Amphora

Chlamyderm

Chlamydia trachomatis vaccine

drug for Chlamydia Infections

solithromycin

Chlamydia trachomatis vaccine

drug for Chlamydia Infections(Virulence blockers)

VPI-201

Drug Details

1. Snapshot

Name of the Therapeutic Agent

Originator

Developing Company

Co-Developer/License Partner

Orphan Drug/Fast Track/Designation

Development Phase

2. Drug Overview

3. Mechanism of Action

4. Current Status

5. Clinical Trial Details

IV. CHLAMYDIA PIPELINE COMPANY BRIEFS

Abera Bioscience AB

BlueWillow Biologics Inc

Evoform Biosciences Inc

Genetic Immunity Inc

Genocea Biosciences Inc

Lead Discovery Center GmbH

Melinta Therapeutics Inc

Prokarium Ltd

QureTech Bio AB

Vault Pharma Inc

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL CHLAMYDIA PIPELINE MARKET

VI. APPENDIX

1. Publisher's Expertise

2. Research Methodology

3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability

I would like to order

Product name: Chlamydia Drug Development Pipeline Study, H2 2018

Product link: <https://marketpublishers.com/r/C6E46C5DB20EN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C6E46C5DB20EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970